Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells

Journal of Gastroenterology

Volumn 47, Issue 8, 2012, Pages 883-895

  Kurokawa, Ken ^a   Tanahashi, Toshihito ^a,b   Iima, Tsutomu ^a   Yamamoto, Yuta ^a   Akaike, Yoko ^a   Nishida, Kensei ^a   Masuda, Kiyoshi ^a   Kuwano, Yuki ^a   Murakami, Yoshiki ^c   Fukushima, Masakazu ^d   Rokutan, Kazuhito ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 Fluorouracil; Colorectal cancer; microRNA; RIP Chip

Indexed keywords

FLUOROURACIL; MESSENGER RNA; MICRORNA;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MYBL2 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SFPQ GENE; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; UP-REGULATION;

EID: 84867572383     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0547-6     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet. 1995; 345:939-44.
3. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041-7.
4. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.
5. Iorns E, Lord CJ, Turner N, et al. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov. 2007;6:556-68.
6. Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling- based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 2003;63:8791-812.
7. Boyer J, Allen WL, McLean EG, et al. Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 2006;66:2765-77.
8. Ooyama A, Takechi T, Toda E, et al. Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006;97:510-22.
9. Karasawa H, Miura K, Fujibuchi W, et al. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci. 2009;100:903-13.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
11. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522-31.
12. Nilsen TW. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet. 2007;23:243-9.
13. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol. 2007;17:118-26.
14. Miranda KC, Huynh T, Tay Y, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006;126:1203-17.
15. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006;11:441-50.
16. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26:462-9.
17. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-66.
18. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene. 2007;26:2799-803.
19. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68: 425-33.
20. Murakami Y, Kazuno H, Emura T, et al. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000;17:277-83.
21. Fukushima M, Fujioka A, Uchida J, et al. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer. 2001;37:1681-7.
22. Boyer J, McLean EG, Aroori S, et al. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res. 2004;10:2158-67.
23. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006;7:3.
24. Allison DB, Cui X, Page GP, et al. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet. 2006;7:55-65.
25. Zhang X, Chen J, Radcliffe T, et al. An array-based analysis of microRNA expression comparing matched frozen and formalinfixed paraffin-embedded human tissue samples. J Mol Diagn. 2008;10:513-9.
26. Wang WX, Wilfred BR, Hu Y, et al. Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes. RNA. 2010;16:394-404.
27. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005;437:1032-7.
28. Mu P, Han YC, Betel D, et al. Genetic dissection of the miR- 17 ∼ 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23:2806-11.
29. Olive V, Bennett MJ, Walker JC, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23:2839-49.
30. Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70:4528-38.
31. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA. 2007;13:151-9.
32. Tan LP, Seinen E, Duns G, et al. A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res. 2009;37:e137.
33. Hayashida Y, Nishibu T, Inoue K, et al. A useful approach to total analysis of RISC-associated RNA. BMC Res Notes. 2009;2:169.
34. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425-36.
35. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008;68:6416-24.
36. Lanza G, Ferracin M, Gafa R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer. 2007;6:54.
37. Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25:2537-45.
38. Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther. 2008;7:1-9.
39. Meng F, Henson R, Lang M, et al. Involvement of human micro- RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130:2113-29.
40. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther. 2008;7: 2152-9.
41. Xia L, Zhang D, Du R, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123:372-9.
42. Rossi L, Bonmassar E, Faraoni I. Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res. 2007;56:248-53.
43. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005;435: 839-43.
44. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133:217-22.
45. Gozani O, Patton JG, Reed R. A novel set of spliceosome-associated proteins and the essential splicing factor PSF bind stably to pre-mRNA prior to catalytic step II of the splicing reaction. EMBO J. 1994;13:3356-67.
46. Rajesh C, Baker DK, Pierce AJ, et al. The splicing-factor related protein SFPQ/PSF interacts with RAD51D and is necessary for homology-directed repair and sister chromatid cohesion. Nucleic Acids Res. 2011;39:132-45.
47. Salton M, Lerenthal Y, Wang SY, et al. Involvement of Matrin 3 and SFPQ/NONO in the DNA damage response. Cell Cycle. 2010;9:1568-76.
48. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and apoptosis. Oncogene. 1999;18:3017-33.
49. Joaquin M, Watson RJ. Cell cycle regulation by the B-Myb transcription factor. Cell Mol Life Sci. 2003;60:2389-401.